Skip to content

Study · Not a test of the peptide alone · 1985

3 results

Synthesis of thymosin alpha 1 by fragment condensation using tert.-butyl side chain protection.

Felix AM, Heimer EP, Wang CT, Lambros TJ, Swistok J, Roszkowski M, Ahmad M, Confalone D, Scott JW, Parker D

International journal of peptide and protein research1 Aug 1985Cited by 8 (Europe PMC)

PMID4066151 (opens in a new tab)DOI10.1111/j.1399-3011.1985.tb03190.x (opens in a new tab)PepBankPUB-04066151
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    Fragment condensation with tert.-butyl side chain protection gave thymosin alpha‑1 in 30% overall yield over the final four stages of synthesis.

    In plain wordsIn the lab, a new synthesis route gave thymosin alpha‑1 in 30% overall yield over the final four stages.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableOverall yield of final synthesis stages
    Study

    n: not reported in source

    chemical synthesis
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Measurements

    overall yield
    30%
    final four stages of synthesis

    Source sentences

    Summary
    to give a 30% overall yield for the final four stages of synthesis (including catalytic hydrogenation of octadecapeptide, coupling, deprotection and purification).
    1 context sentence
    Summary · context
    A novel synthesis of thymosin alpha 1 by classical methods using seven tert.-butyl side chain protected fragments is described.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    The synthetic thymosin alpha‑1 was homogeneous by several analytical methods, and its structure was confirmed by amino acid analysis, NMR, mass spectroscopy and peptide mapping.

    In plain wordsIn the lab, several tests showed the synthetic thymosin alpha‑1 was pure and had the expected structure.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePurity and structure confirmation of synthetic product
    Study

    n: not reported in source

    chemical synthesis
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The product was shown to be homogeneous by thin-layer and paper high voltage electrophoresis, isoelectric focusing analysis, thin-layer chromatography and high performance liquid chromatography.
    1 context sentence
    Summary · context
    Amino acid analysis, optical rotation, 1H-n.m.r. spectroscopy, FAB mass spectroscopy and peptide mapping after tryptic digestion confirmed the structure of thymosin alpha 1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    Three minor stereoisomer contaminants and one wrong-way-opening product were isolated by HPLC and characterized in the synthesis of thymosin alpha‑1.

    In plain wordsIn the lab, the synthesis produced small amounts of three stereoisomer impurities and one side product, which were isolated and identified.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableStereoisomer and side-product contaminants
    Study

    n: not reported in source

    chemical synthesis
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    Three minor stereoisomer contaminants were isolated by HPLC and characterized as [D-Lys14]-thymosin alpha 1, [D-Lys17]-thymosin alpha 1 and [D-Ala3]-thymosin alpha 1 resulting from racemization at Lys14, Lys17 and Ala3 during the coupling of the fragments.
    1 context sentence
    Summary · context
    A final contaminant, isolated by HPLC, was characterized as N alpha-isobutyloxycarbonyl-thymosin alpha 1 (15-28), which results from "wrong way opening" of an activated mixed anhydride.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.